
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics exhibited robust growth in its sales of nanochannel array flowcells, with a 17% increase in 2Q25 and a 7% rise in 3Q25 compared to the same periods in the prior year, indicating strong demand for its genomic technologies. The adjusted revenue for consumables, software, and remaining services saw an 11% year-over-year increase in 2Q25, with consumables and software revenues growing by an impressive 16%. Furthermore, the company anticipates new OGM installations to rise for FY2025 to a range of 20-25, compared to the previous expectation of 15-20, reflecting increasing adoption and market expansion efforts, particularly in regions such as Japan.
Bears say
Bionano Genomics faces significant risks that contribute to a negative outlook, primarily stemming from lower-than-anticipated market uptake and utilization of its products and systems. The company may struggle to secure additional capital necessary for its operations, raising concerns about potential dilution for current shareholders. Furthermore, relying on a conservative EV/Revenue multiple combined with projected sales per share indicates only limited upside potential, thereby highlighting the financial challenges ahead for the company.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares